Home' Australian Pharmacist : Australian Pharmacist May 2016 Contents Australian Pharmacist May 2016 I ©Pharmaceutical Society of Australia Ltd.
Asia-Pacific AD market growing
The Asia-Pacific (APAC) Alzheimer's
disease market will grow from $3 billion in
2014 to $5.1 billion in 2021, representing
a compound annual growth rate of
7.9%, according to business intelligence
provider GBI Research.
The company's report, Alzheimer's
Therapeutics in Asia-Pacific Markets to
2021 -- Growth Driven by Rising Prevalence,
Growing Awareness and Expected Launch
of Disease Modifying Therapies, says that
the main driver of this growth, which will
occur across the APAC countries of India,
China, Australia and Japan, will be rising
and ageing populations, as Alzheimer's
disease is significantly more prevalent
among the elderly.
Additional market drivers include better
diagnostic techniques, improving health
awareness, special healthcare programs,
health insurance coverage, and
increasing treatment affordability.
GBI Research Analyst Gayathri Kanika
said: 'An example of healthcare reforms
is the Japanese Government's recently
approved plan to increase the number
of nurses and care workers in the
country's healthcare system by 2025,
in order to help patients access and
interpret information about their health,
thereby improving knowledge and
diagnoses of Alzheimer's.
'Across the APAC region, the expansion
of health insurance coverage will
increase access to healthcare, also
leading to a rise in Alzheimer's diagnosis
and higher treatment rates.'
The current Alzheimer's pipeline has a
number of late-stage products with the
potential to be approved and launched
in APAC countries during the forecast
period. These include first-in-class Beta-
site Amyloid precursor protein Cleaving
Enzyme (BACE)1 inhibitors and passive
Gayathri Kanika said: 'Three important
anti-beta Amyloid (A/beta) drugs
are Roche's gantenerumab, TauRX
Therapeutics' LMTX and Merck's MK-
8931 (verubecestat), which are in Phase
III development in Australia and Japan,
and will capture significant market
share in these countries after they are
launched late in the forecast period.
'Acetylcholinesterase Inhibitors (AChEIs),
such as Eisai's Aricept (donepezil),
Novartis' Exelon (rivastigmine) and
Janssen's Razadyne (galantamine), will
also continue to capture major patient
share across all Alzheimer's sub-
populations in the four APAC countries.'
In-pharmacy medical centre
Blooms The Chemist has opened a 'MedClinic' medical centre inside its
Penrith Plaza pharmacy.
The initiative follows substantial
customer feedback regarding the
difficulty of securing appointments
with a local GP close to a pharmacy
According to pharmacist Rachel
El-Fawal, the new venture coincides with
a recent retail store refurbishment as
part of the pharmacy's commitment to
the long-term health and wellness of the
'Given a large percentage of our
customers are elderly or largely
immobile due to various health
conditions, this posed a serious
problem, travel-wise, especially during
inclement weather,' she said.
'So our new GP clinic will now offer
these customers the convenience of
visiting their GP and pharmacy within
the one visit to have their prescriptions
dispensed straight away, and to be
referred to a trusted GP for further
professional medical counselling,
'Furthermore, should our customers
be faced with medication changes, a
discontinuing product supply line, or
limited market supply, our in-house GP
will be able to review their medication
and advise appropriate alternatives.'
Blooms The Chemist's also offers
HealthChecks where pharmacists
answer customers' health-related
enquiries and provide health-related
services including cholesterol testing,
blood pressure assessment, diabetes
monitoring, stroke risk assessments,
men's health, travel and natural health
advice, and a script ready service.
ˆ L-R: Jacquie Trinh (Pharmacist) and Cassie Elvy
(Retail Manager) and Rachel El-Fawal (pharmacist).
'By directly referring our Blooms
The Chemist customers to our in-store
GP for further medical advice and
treatment, this will arm individuals with
a comprehensive healthcare plan,' Ms El-
The GP clinic is available to all members
of the community and offers bulk-billing
for consultation services covered by
Medicare. It will run between 9:30am
and 2:30pm, Monday to Friday.
Links Archive Australian Pharmacist April 2016 Australian Pharmacist June 2016 Navigation Previous Page Next Page